Ultragenyx Pharmaceutical Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Ultragenyx Pharmaceutical Inc 公司

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

Ultragenyx Pharmaceutical Inc簡介



公司代碼RARE

公司名稱Ultragenyx Pharmaceutical Inc

上市日期Jan 31, 2014

CEOKakkis (Emil D)

員工數量1294

證券類型Ordinary Share

年結日Jan 31

公司地址60 Leveroni Ct

城市NOVATO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94949

電話14154838800

網址https://www.ultragenyx.com/

公司代碼RARE

上市日期Jan 31, 2014

CEOKakkis (Emil D)

Ultragenyx Pharmaceutical Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.83M

+2.71%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

140.45K

+16.46%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

90.60K

+31.89%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

48.72K

-9.61%

Mr. Michael A. Narachi

Independent Director

26.95K

-1.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

26.95K

-1.47%

Dr. Shehnaaz Suliman, M.D.

Independent Director

20.20K

-1.96%

Dr. Amrit Ray, M.D.

Independent Director

17.63K

-2.24%

Mr. Matthew K. (Matt) Fust

Independent Director

--

Mr. John R. Pinion, II

Chief Quality Officer, Executive Vice President - Translational Sciences

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Emil D. Kakkis, M.D., Ph.D.

President, Chief Executive Officer, Director

2.83M

+2.71%

Mr. Dennis Karl Huang

Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations

140.45K

+16.46%

Mr. Erik Harris

Executive Vice President, Chief Commercial Officer

90.60K

+31.89%

Mr. Howard Horn

Chief Financial Officer, Executive Vice President, Corporate Strategy

48.72K

-9.61%

Mr. Michael A. Narachi

Independent Director

26.95K

-1.47%

Mr. Daniel G. Welch

Independent Chairman of the Board

26.95K

-1.47%

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

業務USD

名稱

營收

佔比

Crysvita royalty revenue

304.00M

45.17%

Crysvita

177.00M

26.30%

Dojolvi

96.00M

14.26%

Evkeeza

59.00M

8.77%

Mepsevii

37.00M

5.50%

地區USD

名稱

營收

佔比

North America

377.00M

56.02%

Latin America

170.00M

25.26%

Europe Middle East and Africa

108.00M

16.05%

Asia Pacific

18.00M

2.67%

業務

地區

業務USD

名稱

營收

佔比

Crysvita royalty revenue

304.00M

45.17%

Crysvita

177.00M

26.30%

Dojolvi

96.00M

14.26%

Evkeeza

59.00M

8.77%

Mepsevii

37.00M

5.50%

股東統計

更新時間: 5月10日週日

持股股東

股東類型

持股股東

佔比

Vanguard Portfolio Management, LLC

5.47%

BlackRock Institutional Trust Company, N.A.

5.47%

State Street Investment Management (US)

5.10%

Vanguard Capital Management, LLC

4.25%

Sands Capital Management, LLC

3.26%

其他

76.45%

持股股東

佔比

Vanguard Portfolio Management, LLC

5.47%

BlackRock Institutional Trust Company, N.A.

5.47%

State Street Investment Management (US)

5.10%

Vanguard Capital Management, LLC

4.25%

Sands Capital Management, LLC

3.26%

其他

76.45%

股東類型

持股股東

佔比

Investment Advisor

47.10%

Investment Advisor/Hedge Fund

25.80%

Hedge Fund

17.03%

Research Firm

4.75%

Individual Investor

3.79%

Sovereign Wealth Fund

1.28%

Venture Capital

0.51%

Pension Fund

0.44%

Bank and Trust

0.40%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

695

106.19M

107.82%

-1.32M

2025Q4

665

100.29M

103.96%

-2.21M

2025Q3

640

97.34M

100.90%

-3.53M

2025Q2

635

97.48M

101.32%

-2.63M

2025Q1

652

96.83M

102.45%

-3.19M

2024Q4

645

94.29M

102.32%

-4.54M

2024Q3

633

93.51M

101.49%

-6.93M

2024Q2

618

95.17M

101.90%

+3.05M

2024Q1

605

86.17M

101.67%

-4.74M

2023Q4

588

86.44M

105.27%

+5.64M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

5.07M

5.26%

+54.55K

+1.09%

Sep 30, 2025

State Street Investment Management (US)

3.69M

3.83%

+1.12M

+43.55%

Sep 30, 2025

Sands Capital Management, LLC

3.77M

3.91%

-173.63K

-4.40%

Sep 30, 2025

JP Morgan Asset Management

3.25M

3.37%

+644.31K

+24.74%

Sep 30, 2025

RTW Investments L.P.

3.26M

3.38%

+1.55M

+90.83%

Sep 30, 2025

Kakkis (Emil D)

2.69M

2.79%

-31.78K

-1.17%

Mar 07, 2025

Baker Bros. Advisors LP

2.77M

2.87%

--

Sep 30, 2025

Wellington Management Company, LLP

1.95M

2.02%

+73.31K

+3.92%

Sep 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Motley Fool Small-Cap Growth ETF

3.73%

Global X Genomics & Biotechnology ETF

3.19%

Franklin Genomic Advancements ETF

1.59%

Virtus LifeSci Biotech Products ETF

1.41%

State Street SPDR S&P Biotech ETF

1.32%

WisdomTree BioRevolution Fund

0.94%

Direxion Daily S&P Biotech Bull 3X Shares

0.81%

Touchstone Sands Capital US Select Growth ETF

0.8%

Goldman Sachs Future Health Care Equity ETF

0.6%

First Trust Multi-Manager Large Growth ETF

0.54%

Motley Fool Small-Cap Growth ETF

佔比3.73%

Global X Genomics & Biotechnology ETF

佔比3.19%

Franklin Genomic Advancements ETF

佔比1.59%

Virtus LifeSci Biotech Products ETF

佔比1.41%

State Street SPDR S&P Biotech ETF

佔比1.32%

WisdomTree BioRevolution Fund

佔比0.94%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.81%

Touchstone Sands Capital US Select Growth ETF

佔比0.8%

Goldman Sachs Future Health Care Equity ETF

佔比0.6%

First Trust Multi-Manager Large Growth ETF

佔比0.54%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據